BioSpace News Archive

Arkstone Medical Solutions, the leading provider of laboratory infectious disease reporting and proactive antimicrobial stewardship, has once again raised the bar in infectious disease analysis for laboratory results, by enhancing the already groundbreaking OneChoice targeted treatment recommendations with the addition of dynamic renal and hepatic dosing adjustments.

BriaCell Therapeutics Corp is pleased to announce that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell’s lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announced a strategic partnership with Center for Breakthrough Medicines, a leading contract development and manufacturing organization dedicated to accelerating the commercialization of cell and gene therapies.

Strata Oncology, Inc. today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer.

Pivotal clinical trial of OstomyCure’s proprietary TIES implant for people with an ileostomy

AAPS to Oversee Scientific Programming for INTERPHEX Attendees of National Biotechnology Conference can register for INTERPHEX free of charge

Visura Technologies, Inc. announced today the completion of the company’s $4 million Series B financing.

Pyramid Biosciences, Inc. has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference.

Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx), a clinical development company, today announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis.

Novan, Inc., announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 12:00 PM ET.